AVITA Medical to Announce Third Quarter 2023 Financial Results
October 19 2023 - 3:05PM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company leading the development and commercialization of
first-in-class devices and autologous cellular therapies for skin
restoration, today announced that it will report its third quarter
2023 financial results after the close of the U.S. financial
markets on Thursday, November 9, 2023. AVITA Medical will host a
conference call and webcast that day at 1:30 p.m. Pacific Time
(Friday, November 10, 2023, at 7:30 a.m. Australian Eastern
Daylight Time) to discuss its financial results and recent business
highlights.
To access the live call via telephone, please register in
advance using the link here. Upon registering, each participant
will receive an email confirmation with dial-in numbers and a
unique personal PIN that can be used to join the call.
The live webcast of the call may be accessed by visiting the
Investor Relations section of the AVITA Medical website at
https://ir.avitamedical.com/events-and-presentations. A replay of
the webcast will be available shortly after the conclusion of the
call.
About AVITA Medical, Inc.AVITA Medical® is a
regenerative medicine company leading the development and
commercialization of devices and autologous cellular therapies for
skin restoration. The RECELL® System technology platform, approved
by the Food and Drug Administration for the treatment of thermal
burn wounds and full-thickness skin defects and for repigmentation
of stable depigmented vitiligo lesions, harnesses the regenerative
properties of a patient’s own skin to create Spray-On Skin™ cells.
Delivered at the point-of-care, RECELL enables improved clinical
outcomes. RECELL is the catalyst of a new treatment paradigm and
AVITA Medical is leveraging its proven and differentiated
capabilities to develop first-in-class cellular therapies for
multiple indications.
In international markets, our products are approved under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, full-thickness skin defects, and
vitiligo. The RECELL System is TGA-registered in Australia,
received CE-mark approval in Europe and has PMDA approval in
Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:Jessica
EkebergPhone +1-661-904-9269
investor@avitamedical.commedia@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA
Medical, Inc.
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From May 2023 to May 2024